Jennifer R. Stephens

817 citations

23 papers · 486 indexed · h-index 9

Co-authors: Michele Dowless Louis F. Stancato Bruce W. Konicek Wayne Blosser Ann M. McNulty Philip W. Iversen Jeremy R. Graff Luc Furic
Topics: Cancer Mechanisms and Therapy (6 papers)PI3K/AKT/mTOR signaling in cancer (5 papers)Hepatocellular Carcinoma Treatment and Prognosis (4 papers)
Cited by: Genetics Oncology Pathology and Forensic Medicine
Journals: Blood Cancer Research Clinical Cancer Research
Partner nations: United States Canada China

In The Last Decade

Jennifer R. Stephens

22 papers receiving 480 citations

Peers

Countries citing papers authored by Jennifer R. Stephens

Since Specialization

Citations

This map shows the geographic impact of Jennifer R. Stephens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer R. Stephens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer R. Stephens more than expected).

Fields of papers citing papers by Jennifer R. Stephens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer R. Stephens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer R. Stephens. The network helps show where Jennifer R. Stephens may publish in the future.

Co-authorship network of co-authors of Jennifer R. Stephens

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer R. Stephens. A scholar is included among the top collaborators of Jennifer R. Stephens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer R. Stephens. Jennifer R. Stephens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pirtobrutinib preclinical characterization: a highly selective, non-covalent (reversible) BTK inhibitor 2023 ·Blood ·Eliana B Gómez,Kevin Ebata,(unknown),Mary S. Rosendahl,(unknown),Tony Morales,Lauren Hanson,(unknown),Xueqian Gong,Jennifer R. Stephens,Wenjuan Wu,(unknown),Karin S. Ku,Richard A. Walgren,Paolo Abada,Joshua A. Ballard,C.K. Allerston,Barbara J. Brandhuber	56
2	Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells 2020 ·Oncotarget ·Lacey M. Litchfield,Karsten Boehnke,Manisha Brahmachary,Cecilia Mur,Bi Chen,Jennifer R. Stephens,J.M. Sauder,(unknown),Ann M. McNulty,Xiang S. Ye,Wenjuan Wu,Marı́a José Lallena,Xueqian Gong,Farhana F. Merzoug,Valerie M. Jansen,Sean G. Buchanan	17
3	In Vivo Pre-Clinical Evaluation of LOXO-305 Alone and in Combination with Venetoclax, Rituximab, R-CHOP or Obinutuzumab on Human Xenograft Lymphoma Tumor Models in Mice 2020 ·Blood ·Eliana B Gómez,Wenjuan Wu,Jennifer R. Stephens,Mary S. Rosendahl,Barbara J. Brandhuber	6
4	Abstract 1761: Inhibition of PI3K/AKT/mTOR signaling by a dual PI3K/mTOR inhibitor (LY3023414) potentiates the antitumor efficacy of the Chk1 inhibitor prexasertib (LY2606368) in models of human high-grade serous ovarian cancer (HGSOC) 2019 ·Cancer Research ·Jack Dempsey,Gregory P. Donoho,Philip W. Iversen,Jennifer R. Stephens,Ann M. McNulty,Ricardo Martínez,Christoph Reinhard,Louis F. Stancato,Aimee Bence Lin,Wenjuan Wu	3
5	Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy 2019 ·Oncotarget ·Caitlin D. Lowery,Wayne Blosser,Michele Dowless,(unknown),(unknown),Jennifer R. Stephens,Bronislaw Pytowski,(unknown),Louis F. Stancato,Beverly L. Falcón	14
6	Abstract 3508: Combination of the Chk1 inhibitor (prexasertib) with a PI3K/mTOR inhibitor (LY3023414) induces synergistic anti-tumor activity in triple negative breast cancer (TNBC) models 2019 ·Cancer Research ·Wenjuan Wu,Gregory P. Donoho,Philip W. Iversen,Jack Dempsey,Andrew Capen,Mark Castanares,Jennifer R. Stephens,Karsten Boehnke,(unknown),Aimee Bence Lin	3
7	Abstract 336: Anti-tumor activity of the Chk1 inhibitor prexasertib (LY2606368) as a single agent in triple negative breast cancer models 2018 ·Cancer Research ·Wenjuan Wu,Constance King,Gregory P. Donoho,Philip W. Iversen,Andrew Capen,Mark Castanares,Jennifer R. Stephens,Yan Ding,Susan E. Pratt,Ricardo Martínez,Sean G. Buchanan,Christoph Reinhard,Richard P. Beckmann,Aimee Bence Lin	4
8	Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors 2018 ·Oncotarget ·Bruce W. Konicek,Andrew Capen,Kelly M. Credille,Philip J. Ebert,Beverly L. Falcón,(unknown),Bharvin K.R. Patel,Victoria L. Peek,Jennifer R. Stephens,Julie Stewart,Stephanie L. Stout,David E. Timm,Suzane L. Um,Melinda D. Willard,Isabella H. Wulur,Yi Arial Zeng,Yong Wang,Richard A. Walgren,S. Betty Yan	38
9	The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma 2017 ·Clinical Cancer Research ·Caitlin D. Lowery,(unknown),Michele Dowless,Wayne Blosser,Beverly L. Falcón,Julie Stewart,Jennifer R. Stephens,Richard P. Beckmann,Aimee Bence Lin,Louis F. Stancato	53
10	Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α 2017 ·Clinical Cancer Research ·Caitlin D. Lowery,Wayne Blosser,Michele Dowless,(unknown),Jennifer R. Stephens,Huiling Li,David Surguladze,Nick Loizos,Debra Luffer‐Atlas,Gerard J. Oakley,Qianxu Guo,Seema Iyer,Brian P. Rubin,Louis F. Stancato	26
11	MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping 2017 ·Investigational New Drugs ·S. Betty Yan,Suzane L. Um,Victoria L. Peek,Jennifer R. Stephens,Wei Zeng,Bruce W. Konicek,Ling Liu,Jason R. Manro,Volker Wacheck,Richard A. Walgren	33
12	Abstract 519: Antitumor activity of MET antibody emibetuzumab (LY2875358) in combination with EGFR inhibitors in erlotinib resistant (ER) xenograft mouse models 2017 ·Cancer Research ·Suzane L. Um,Victoria L. Peek,Jennifer R. Stephens,(unknown),(unknown),Joel D. Cook,Isabella H. Wulur,(unknown),Sudhakar Chintharlapalli,Robert J. Evans,William J. Feaver,Lysiane Huber,Linda N. Lee,Ling Liu,Liandong Ma,Ruslan D. Novosiadly,Volker Wacheck,S. Betty Yan	2
13	Abstract 583: The CDK4/6 inhibitor abemaciclib induces synergistic immune activation and antitumor efficacy in combination with PD-L1 blockade 2017 ·Cancer Research ·Jack Dempsey,Lysiane Huber,Amélie Forest,Jennifer R. Stephens,Thompson N. Doman,Jason R. Manro,Andrew Capen,(unknown),Gregory P. Donoho,Sean G. Buchanan,Alfonso de Dios,Kyla Driscoll,Michael Kalos,Ruslan D. Novosiadly,Richard P. Beckmann,David Schaer	2
14	Abstract 2647: Merestinib (LY2801653), targeting several oncokinases including NTRK1/2/3, shows potent anti-tumor effect in colorectal cell line- and patient-derived xenograft (PDX) model bearing TPM3-NTRK1 fusion 2016 ·Cancer Research ·Bruce W. Konicek,(unknown),Andrew Capen,John Calley,Kelly M. Credille,Philip J. Ebert,(unknown),Bharvin K.R. Patel,Victoria L. Peek,Jennifer R. Stephens,Suzane L. Um,Melinda D. Willard,Isabella H. Wulur,Yi Arial Zeng,Richard A. Walgren,S. Betty Yan	1
15	Abstract 2458: Targeting checkpoint kinase 1 (CHK1) with the small molecule inhibitor LY2606368 mesylate monohydrate in models of high-risk pediatric cancer yields significant antitumor effects 2016 ·Cancer Research ·Caitlin D. May,Richard P. Beckmann,Wayne Blosser,Michele Dowless,(unknown),Teresa F. Burke,Gerard J. Oakley,Jennifer R. Stephens,Julie Stewart,Beverly L. Falcón,Louis F. Stancato	1
16	Abstract 4403: Preclinical evaluation of LY2801653, an orally bioavailable small molecule oncokinase inhibitor, in cholangiocarcinoma models 2014 ·Cancer Research ·S. Betty Yan,Suzane L. Um,Victoria L. Peek,Megan N. Thobe,Kelly M. Credille,Jennifer R. Stephens,Jason R. Manro,Darryl Ballard,(unknown),Joel D. Cook,Bruce W. Konicek,Jeremy R. Graff,Timothy R. Holzer,Richard A. Walgren	1
17	Abstract 5465: LY2875358, a bivalent MET antibody with anti-tumor activity through blocking HGF as well as inducing degradation of MET, differentiates from a one-armed 5D5 MET antibody. 2013 ·Cancer Research ·Wei Zeng,Victoria L. Peek,(unknown),Jonathan W. Tetreault,Jinqi Xia,Jennifer R. Stephens,Kelly M. Credille,Darryl Ballard,(unknown),Jirong Lu,Chi-Kin Chow,Peter Vaillancourt,Ying Tang,S. Betty Yan,Ling Liu	3
18	Abstract 2734: c-Met antibody LY2875358 (LA480) shows differential antitumor effects in non-small cell lung cancer 2012 ·Cancer Research ·Wei Zeng,Lei Yan,Victoria L. Peek,(unknown),Jonathan W. Tetreault,Jinqi Xia,Chi-Kin Chow,Jason R. Manro,Jennifer R. Stephens,(unknown),Ying Tang,Peter Vaillancourt,Jirong Lu,(unknown),(unknown)	5
19	Abstract 2738: c-Met antibody LY2875358 (LA480) has pre-clinical enhanced efficacy with gastric cancer standard-of-care in vitro and in vivo 2012 ·Cancer Research ·(unknown),Victoria L. Peek,Wei Zeng,Lei Yan,Jonathan W. Tetreault,Jinqi Xia,Jirong Lu,Chi-Kin Chow,Jason R. Manro,Jennifer R. Stephens,Farhana F. Merzoug,Peter Vaillancourt,S. Betty Yan,Ling Liu	4
20	Therapeutic Inhibition of MAP Kinase Interacting Kinase Blocks Eukaryotic Initiation Factor 4E Phosphorylation and Suppresses Outgrowth of Experimental Lung Metastases 2011 ·Cancer Research ·Bruce W. Konicek,Jennifer R. Stephens,Ann M. McNulty,Nathaniel Robichaud,Robert B. Peery,Chad A. Dumstorf,Michele Dowless,Philip W. Iversen,Stephen H. Parsons,(unknown),Denis McCann,Jerry Pelletier,Luc Furic,Jonathan M. Yingling,Louis F. Stancato,Nahum Sonenberg,Jeremy R. Graff	159

About Jennifer R. Stephens

Jennifer R. Stephens is a scholar working on Hepatology, Pathology and Forensic Medicine and Genetics, having authored 23 papers that have together received 486 indexed citations. Recurring topics across this work include Cancer Mechanisms and Therapy (6 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). The work is most often cited by research in Genetics (82 citations), Oncology (175 citations) and Pathology and Forensic Medicine (100 citations). Jennifer R. Stephens has collaborated with scholars based in United States, Canada and China. Frequent co-authors include Michele Dowless, Louis F. Stancato, Bruce W. Konicek, Wayne Blosser, Ann M. McNulty, Philip W. Iversen, Jeremy R. Graff, Luc Furic, Jonathan M. Yingling and Richard A. Walgren. Their work appears in journals such as Blood, Cancer Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact